- Home
- GALT vs GRABW Comparison
GALT vs GRABW Comparison
Compare GALT & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- GRABW
- Stock Information
- Founded
- GALT 2000
- GRABW 2012
- Country
- GALT United States
- GRABW Singapore
- Employees
- GALT N/A
- GRABW 11267
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- GRABW Business Services
- Sector
- GALT Health Care
- GRABW Consumer Discretionary
- Exchange
- GALT Nasdaq
- GRABW Nasdaq
- Market Cap
- GALT 83.5M
- GRABW N/A
- IPO Year
- GALT N/A
- GRABW N/A
- Fundamental
- Price
- GALT $2.45
- GRABW $0.39
- Analyst Decision
- GALT Buy
- GRABW
- Analyst Count
- GALT 2
- GRABW 0
- Target Price
- GALT $6.00
- GRABW N/A
- AVG Volume (30 Days)
- GALT 1.4M
- GRABW 54.7K
- Earning Date
- GALT 08-12-2025
- GRABW 02-21-2025
- Dividend Yield
- GALT N/A
- GRABW N/A
- EPS Growth
- GALT N/A
- GRABW N/A
- EPS
- GALT N/A
- GRABW N/A
- Revenue
- GALT N/A
- GRABW $2,686,000,000.00
- Revenue This Year
- GALT N/A
- GRABW N/A
- Revenue Next Year
- GALT N/A
- GRABW N/A
- P/E Ratio
- GALT N/A
- GRABW N/A
- Revenue Growth
- GALT N/A
- GRABW 21.65
- 52 Week Low
- GALT $0.73
- GRABW $0.15
- 52 Week High
- GALT $3.90
- GRABW $0.59
- Technical
- Relative Strength Index (RSI)
- GALT 61.39
- GRABW 38.64
- Support Level
- GALT $2.21
- GRABW $0.33
- Resistance Level
- GALT $3.90
- GRABW $0.37
- Average True Range (ATR)
- GALT 0.47
- GRABW 0.03
- MACD
- GALT 0.09
- GRABW -0.00
- Stochastic Oscillator
- GALT 40.84
- GRABW 8.33
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About GRABW Grab Holdings Limited Warrant
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.